Get the Stockscreener App
1.015
13.25%
-0.155
Biocardia Inc stock is traded at $1.015, with a volume of 803.63K.
It is down -13.25% in the last 24 hours and down -1.46% over the past month.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$1.17
Open:
$1.16
24h Volume:
803.63K
Relative Volume:
0.29
Market Cap:
$15.11M
Revenue:
$3,000
Net Income/Loss:
$-7.78M
P/E Ratio:
-0.9811
EPS:
-1.0346
Net Cash Flow:
$-7.49M
1W Performance:
-18.15%
1M Performance:
-1.46%
6M Performance:
-22.52%
1Y Performance:
-51.67%
1-Day Range:
$1.00
$1.16
1-Week Range:
$1.00
$1.255
52-Week Range:
$0.7765
$2.45
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia Inc
Sector
Industry
Phone
650-226-0123
Address
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.49 | 2.97B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
20.01 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.20 | 349.09M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
4.72 | 358.07M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
47.37 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-21 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Stock (BCDA) Latest News
BCDABioCardia Inc Latest SEC Filings - Finviz
BioCardia (BCDA) CFO granted 60,483 RSUs as stock compensation - Stock Titan
Form 4 Biocardia Inc For: 1 July By Investing.com - Investing.com UK
BioCardia (BCDA) CEO Peter Altman granted 110,625 fully vested RSUs - Stock Titan
BioCardia (BCDA) SVP awarded 39,521 RSUs fully vesting on June 29, 2026 - Stock Titan
BCDA Q1 2026 Earnings: Wider-than-Expected Loss Amid No Revenue, Stock Jumps 10%Debt Analysis Report - dars.gov.et
Price to book forward of BioCardia, Inc. – NASDAQ:BCDA - TradingView
BioCardia, Inc. Actuals & Estimates (NASDAQ:BCDA) - TradingView
BCDA Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of BioCardia, Inc. – NASDAQ:BCDA - TradingView
BioCardia Inc (BCDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to EBITDA forward of BioCardia, Inc. – NASDAQ:BCDA - TradingView
BioCardia director Simon Stertzer buys $103,584 in common stock - Investing.com UK
BioCardia director Simon Stertzer buys $103,584 in common stock By Investing.com - Investing.com South Africa
Form 4 Biocardia Inc For: 24 June By Investing.com - Investing.com Australia
Director Stertzer (BCDA) adds 109,200 BioCardia shares in open-market buys - Stock Titan
BioCardia Inc (BCDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioCardia president & CEO Peter Altman buys $2,043 in stock - Investing.com UK
BioCardia president & CEO Peter Altman buys $2,043 in stock By Investing.com - Investing.com South Africa
Form 4 Biocardia Inc For: 22 June By Investing.com - Investing.com Nigeria
BioCardia (BCDA) CEO adds 2,300 shares in open-market buys - Stock Titan
BioCardia (BCDA) Moves Higher Near Resistance – Testing Key LevelsMomentum Stock Picks - dars.gov.et
BioCardia shares rally after FDA supports regulatory path for heart failure therapy (BCDA) - MSN
BioCardia (BCDA) Shares Strategic Business Update Following Capi - GuruFocus
BioCardia Outlines 2026 Strategic Priorities: Japan CardiAMP Submission, U.S. Expansion, and New Partnership Opportunities – Minichart - Minichart
BioCardia's High-Stakes Gambit: A Japan-First Strategy for Heart Therapy - BriefGlance
symbol__ Stock Quote Price and Forecast - CNN
BioCardia plans Japan regulatory submission for heart therapy By Investing.com - Investing.com South Africa
BioCardia plans Japan regulatory submission for heart therapy - Investing.com
BioCardia Inc (BCDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioCardia Outlines 2026 CardiAMP Strategy and Milestones - TipRanks
BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities - The Manila Times
BioCardia targets Japan PMDA submission for CardiAMP, advances U.S. trial and partnership opportunities - TradingView
BioCardia (NASDAQ: BCDA) details Japan approval push and 2026 catalysts - Stock Titan
BioCardia Inc (BCDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioCardia Inc (BCDA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioCardia Inc (BCDA) Institutional Confidence - TradingKey
BioCardia Inc (BCDA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioCardia Inc (BCDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioCardia Inc (BCDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biocardia Inc Stock (BCDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biocardia Inc Stock (BCDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STERTZER SIMON H | Director |
Jun 23 '26 |
Buy |
1.00 |
39,000 |
39,000 |
166,338 |
| Altman Peter | President and CEO |
Jun 17 '26 |
Buy |
0.85 |
1,500 |
1,275 |
299,766 |
| Altman Peter | President and CEO |
Jun 18 '26 |
Buy |
0.96 |
800 |
768 |
300,566 |
| Altman Peter | President and CEO |
Jun 09 '26 |
Buy |
0.85 |
5,000 |
4,250 |
298,266 |
| Altman Peter | President and CEO |
May 20 '26 |
Buy |
0.92 |
1,500 |
1,380 |
293,266 |
| Altman Peter | President and CEO |
May 19 '26 |
Buy |
0.95 |
200 |
190 |
291,766 |
| Altman Peter | President and CEO |
May 18 '26 |
Buy |
0.92 |
5,700 |
5,244 |
291,566 |
| Altman Peter | President and CEO |
May 15 '26 |
Buy |
1.02 |
5,100 |
5,202 |
285,866 |
| Altman Peter | President and CEO |
Apr 29 '26 |
Buy |
1.11 |
5,000 |
5,550 |
280,766 |
| Altman Peter | President and CEO |
Apr 20 '26 |
Buy |
1.23 |
600 |
738 |
275,366 |
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):